Business Context and Reporting Period
This Form 6-K filing by Sanofi-Aventis covers the month of January 2008. The registrant is a foreign private issuer based in Paris, France, reporting pursuant to Rule 13a-16 under the Securities Exchange Act of 1934. The filing serves to incorporate two press releases issued during the period regarding strategic agreements and regulatory approvals.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity figures. This report is informational in nature and focuses on corporate developments rather than financial performance metrics.
Material Changes and Corporate Developments
- Strategic Partnership: On January 3, 2008, Sanofi Pasteur entered into an agreement with Crucell to develop next-generation biologicals against Rabies.
- Regulatory Approval: On January 28, 2008, the company received approval in Japan for its products Clexane and Lovenox.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, outlook projections, or a discussion of risks and contingencies. The document strictly references the attached press releases as Exhibits 99.1 and 99.2.
Key Facts for Investor Verification
- Verify the specific terms and financial implications of the Sanofi Pasteur and Crucell agreement regarding Rabies biologicals.
- Confirm the commercial impact and market size associated with the approval of Clexane/Lovenox in Japan.
- Note that this filing contains no quantitative financial results for the period.